Heineken has alerted British hospitality establishments that the expanding use of GLP-1 medications could negatively impact beer and cider sales. The Netherlands-based brewer distributed a presentation to UK customers earlier this month outlining concerns that weight-loss drugs such as Ozempic and Wegovy may diminish alcohol consumption by creating sensations of fullness and reducing the frequency of traditional multi-pint drinking sessions.
The company recommended that bars and pubs adopt strategies to mitigate potential revenue losses, including promoting half-pint servings, expanding low- and zero-alcohol beverage offerings, and pairing drinks with small food plates. Heineken noted that observations of GLP-1 users indicate a shift toward smaller portions, lower-alcohol choices, and premium products, reflecting a broader consumer movement toward health consciousness and intentional purchasing decisions.
Research data presents mixed signals regarding the magnitude of this trend. JP Morgan research indicates 10 million Americans adopted GLP-1 medication in the previous year. Multiple market research firms including Circana, NIQ, and KAM have documented reduced drinking among GLP-1 users, while other beverage industry players offered different perspectives. Diageo, maker of Guinness, suggested any GLP-1-related impact should be manageable, and Carlsberg stated available data did not support claims of reduced beer consumption from weight-loss drug users.
Heineken emphasized it continues monitoring how consumer behaviors evolve and noted that consumption pattern changes reflect multiple broader trends beyond GLP-1 use alone. The brewer cited British beer market data showing nearly £14 billion in annual sales across pubs, bars, and restaurants, with no- and low-alcohol products representing less than £300 million of that total.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI